Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Paclitaxel, PD-1/PD-L1 Inhibitor, and SBRT as Neoadjuvant Therapy in Older Patients With Resectable NSCLC
NCT07754812Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 4 trial of paclitaxel oral solution in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Jun 2026; status: recruiting.
02
Drugs
paclitaxel oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07754812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754812.